MobiHealth News December 7, 2021
The company’s digital therapeutic aimed at treating depression in teens, SparkRx, was launched in October.
Limbix, maker of a prescription digital therapeutic aimed at treating depression in teens, scooped up $15 million in Series A2 funding.
The round was led by GSR Ventures, with participation from Digital Garage, Storm Ventures, Bixink, DN Capital, Korean Investment Partners, E& Investment, Gaingels, MVP, Operator Partners, Mana Ventures and Pacific Health Ventures.
Limbix announced its $9 million Series A in May 2020. The company said its A2 brings its total raise to $31 million.
WHAT IT DOES
Limbix is the creator of SparkRx, a prescription digital therapeutic that uses the principles of cognitive behavioral therapy to address depression in teens and young adults ages...
Today's Sponsors
Today's Sponsor